Patents by Inventor Patrick Stephen Johnson
Patrick Stephen Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11930616Abstract: A thermal component has a shield portion and a heat exchanger portion. The shield portion includes a plurality of cells adapted to inhibit radio radiation (RF) having a frequency within a target frequency range, while the heat exchanger portion includes a plurality of elongated channels, each one of the elongated channels being physically connected to and in fluid communication with at least one corresponding cell of the plurality of cells.Type: GrantFiled: October 18, 2019Date of Patent: March 12, 2024Assignee: Microsoft Technology Licensing, LLCInventors: Rob Huala, Nanqiang Zhu, Donovan D. Van Sleet, Aaron Ray Paff, Andrew Douglas Delano, Patrick Stephen Johnson
-
Publication number: 20220316826Abstract: A water redistribution system for adiabatically pre-cooled dry coolers having stacked adiabatic panels, the water redistribution system located between upper and lower adiabatic panels and having a plurality of alternating baffles arranged to reduce water free-fall height and resultant splashing. Upwardly turned flanges at the top of each baffle inhibit the travel of water out of the interior water channel.Type: ApplicationFiled: April 1, 2022Publication date: October 6, 2022Inventors: Kenneth Calvin Wright, JR., Patrick Stephen Johnson
-
Patent number: 11377425Abstract: The present invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.Type: GrantFiled: December 19, 2019Date of Patent: July 5, 2022Assignee: Leo Pharma A/SInventors: Kevin Neil Dack, Xifu Liang, Mogens Larsen, Mark Andrews, Alan Stuart Jessiman, Mia Nørreskov Burhardt, Patrick Stephen Johnson, Peter Andersen, Lars Jørgensen
-
Publication number: 20210120698Abstract: A thermal component has a shield portion and a heat exchanger portion. The shield portion includes a plurality of cells adapted to inhibit radio radiation (RF) having a frequency within a target frequency range, while the heat exchanger portion includes a plurality of elongated channels, each one of the elongated channels being physically connected to and in fluid communication with at least one corresponding cell of the plurality of cells.Type: ApplicationFiled: October 18, 2019Publication date: April 22, 2021Inventors: Rob HUALA, Nanqiang ZHU, Donovan D. VAN SLEET, Aaron Ray PAFF, Andrew Douglas DELANO, Patrick Stephen JOHNSON
-
Patent number: 10934282Abstract: The present invention relates to a compound according to general formula (I) wherein X represents N or CH; R1 is —CN, (C1-C6)alkyl, (C3-C7)cycloalkyl, (3-7 membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C3-C7)cycloalkyl(C1-C4)alkyl, (3-7 membered)heterocycloalkyl-(C1-C4)alkyl or (5-6 membered)heteroaryl-(C1-C4)alkyl; R2 is halogen, cyano, (C1-C4)alkyl or (C3-C7)cycloalkyl; R3 is halogen, cyano, (C1-C4)alkyl, (C1-C4)haloalkyl or (C3-C7)cycloalkyl; R4 is (C1-C4)alkyl or (C1-C4)haloalkyl; R5 is (C1-C6)alkyl, (C3-C7)cycloalkyl, (C1-C6)alkyl-(C3-C7)cycloalkyl, (C3-C7)cycloalkyl-(C1-C6)alkyl, (3-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl or —ORa. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds and to intermediates for preparation of said compounds.Type: GrantFiled: May 15, 2020Date of Patent: March 2, 2021Assignee: LEO Pharma A/SInventors: Alan Stuart Jessiman, Patrick Stephen Johnson, Kristoffer Maansson, Morten Dahl Sørensen
-
Publication number: 20200291010Abstract: The present invention relates to a compound according to general formula (I) wherein X represents N or CH; R1 is —CN, (C1-C6)alkyl, (C3-C7)cycloalkyl, (3-7 membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C3-C7)cycloalkyl(C1-C4)alkyl, (3-7 membered)heterocycloalkyl-(C1-C4)alkyl or (5-6 membered)heteroaryl-(C1-C4)alkyl; R2 is halogen, cyano, (C1-C4)alkyl or (C3-C7)cycloalkyl; R3 is halogen, cyano, (C1-C4)alkyl, (C1-C4)haloalkyl or (C3-C7)cycloalkyl; R4 is (C1-C4)alkyl or (C1-C4)haloalkyl; R5 is (C1-C6)alkyl, (C3-C7)cycloalkyl, (C1-C6)alkyl-(C3-C7)cycloalkyl, (C3-C7)cycloalkyl-(C1-C6)alkyl, (3-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl or —ORa. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds and to intermediates for preparation of said compounds.Type: ApplicationFiled: May 15, 2020Publication date: September 17, 2020Inventors: Alan Stuart JESSIMAN, Patrick Stephen JOHNSON, Kristoffer MAANSSON, Morten Dahl SØRENSEN
-
Patent number: 10662181Abstract: The present invention relates to a compound according to general formula (I) wherein X represents N or CH; R1 is —CN, (C1-C6)alkyl, (C3-C7)cycloalkyl, (3-7 membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C3-C7)cycloalkyl(C1-C4)alkyl, (3-7 membered)heterocycloalkyl-(C1-C4)alkyl or (5-6 membered)heteroaryl-(C1-C4)alkyl; R2 is halogen, cyano, (C1-C4)alkyl or (C3-C7)cycloalkyl; R3 is halogen, cyano, (C1-C4)alkyl, (C1-C4)haloalkyl or (C3-C7)cycloalkyl; R4 is (C1-C4)alkyl or (C1-C4)haloalkyl; R5 is (C1-C6)alkyl, (C3-C7)cycloalkyl, (C1-C6)alkyl-(C3-C7)cycloalkyl, (C3-C7)cycloalkyl-(C1-C6)alkyl, (3-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl or —ORa. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds and to intermediates for preparation of said compounds.Type: GrantFiled: July 11, 2017Date of Patent: May 26, 2020Assignee: LEO Pharma A/SInventors: Alan Stuart Jessiman, Patrick Stephen Johnson, Kristoffer Maansson, Morten Dahl Sørensen
-
Patent number: 10494363Abstract: The present invention relates to a compound according to formula (I) wherein R1 is selected from the group consisting of 5- and 6-membered heteroaryl, (C1-C6)alkyl, (C3-C6)cycloalkyl, (4-6)-membered heterocycloalkyl and phenyl; R2 is selected from (C1-C3)alkyl and halo(C1-C3)alkyl; R3 is selected from phenyl, 5-membered heteroaryl and 6-membered heteroaryl; R4 is selected from hydrogen, halogen, (C1-C4)alkyl and halo(C1-C4)alkyl; X1 is selected from CH, C(Rb) and N, X2 is selected from CH and N; Y is selected from —NH— and —O—; m is 0 or 1; n is 0 or 1; L represents a bond, —O—, —NH— or —N(Rc)—; or pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.Type: GrantFiled: September 13, 2016Date of Patent: December 3, 2019Assignee: Leo Pharma A/SInventors: Patrick Stephen Johnson, Kevin Neil Dack, Krister Henriksson
-
Publication number: 20190284177Abstract: The present invention relates to a compound according to general formula (I) wherein X represents N or CH; R1 is —CN, (C1-C6)alkyl, (C3-C7)cycloalkyl, (3-7 membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C3-C7)cycloalkyl(C1-C4)alkyl, (3-7 membered)heterocycloalkyl-(C1-C4)alkyl or (5-6 membered)heteroaryl-(C1-C4)alkyl; R2 is halogen, cyano, (C1-C4)alkyl or (C3-C7)cycloalkyl; R3 is halogen, cyano, (C1-C4)alkyl, (C1-C4)haloalkyl or (C3-C7)cycloalkyl; R4 is (C1-C4)alkyl or (C1-C4)haloalkyl; R5 is (C1-C6)alkyl, (C3-C7)cycloalkyl, (C1-C6)alkyl-(C3-C7)cycloalkyl, (C3-C7)cycloalkyl-(C1-C6)alkyl, (3-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl or —ORa. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds and to intermediates for preparation of said compounds.Type: ApplicationFiled: July 11, 2017Publication date: September 19, 2019Inventors: Alan Stuart JESSIMAN, Patrick Stephen JOHNSON, Kristoffer MAANSSON, Morten Dahl SØRENSEN
-
Publication number: 20180258080Abstract: The present invention relates to a compound according to formula (I) wherein R1 is selected from the group consisting of 5- and 6-membered heteroaryl, (C1-C6)alkyl, (C3-C6)cycloalkyl, (4-6)-membered heterocycloalkyl and phenyl; R2 is selected from (C1-C3)alkyl and halo(C1-C3)alkyl; R3 is selected from phenyl, 5-membered heteroaryl and 6-membered heteroaryl; R4 is selected from hydrogen, halogen, (C1-C4)alkyl and halo(C1-C4)alkyl; X1 is selected from CH, C(Rb) and N, X2 is selected from CH and N; Y is selected from —NH— and —O—; m is 0 or 1; n is 0 or 1; L represents a bond, —O—, —NH— or —N(Rc)—; or pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.Type: ApplicationFiled: September 13, 2016Publication date: September 13, 2018Inventors: Patrick Stephen JOHNSON, Kevin Neil DACK, Krister HENRIKSSON
-
Publication number: 20160363971Abstract: A thermal control system that includes a combination of active and passive components is described herein. In one or more implementation, the thermal control system compensates for non-uniformities in a temperature profile for an arrangement of components within a computing device. One or more active components of the thermal control system transfer heat away from heat-generating devices by active means, such as active transfer to a moving fluid that is driven by a blower or fan. Additionally, one or more passive components are positioned to transfer heat to selected areas of the device using passive transfer devices, such as heat-pipes and thermal spreaders made of conductive materials. The active and passive components operate together to compensate for temperature variations across the device surfaces, produce a controlled temperature profile having greater uniformity, reduce overall differences in surface temperatures, and provide greater capability for heat dissipation.Type: ApplicationFiled: June 9, 2015Publication date: December 15, 2016Inventors: Andrew Douglas Delano, Patrick Stephen Johnson, Guy Robert Wagner
-
Patent number: 8916593Abstract: The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.Type: GrantFiled: May 4, 2011Date of Patent: December 23, 2014Assignee: Pfizer Inc.Inventors: Mark Edward Bunnage, Andrew Simon Cook, Jingrong Jean Cui, Kevin Nell Dack, Judith Gail Deal, Danlin Gu, Mingying He, Patrick Stephen Johnson, Ted William Johnson, Phuong Thi Quy Le, Cynthia Louise Palmer, Hong Shen
-
Publication number: 20130196952Abstract: The invention relates to compounds of Formula (1) and to processes for the preparation of intermediates used in the preparation of compositions containing and the uses of such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.Type: ApplicationFiled: May 4, 2011Publication date: August 1, 2013Applicant: PFIZER INC.Inventors: Mark Edward Bunnage, Andrew Simon Cook, Jingrong Jean Cui, Kevin Nell Dack, Judith Gail Deal, Danlin Gu, Mingying He, Patrick Stephen Johnson, Ted William Johnson, Phuong Thi Quy Le, Cynthia Louise Palmer, Hong Shen
-
Patent number: 8093400Abstract: The present invention provides compounds of formula (I), or pharmaceutically acceptable derivatives thereof wherein the variables Z, Q, Ring A, V, X, Y and Y? are as defined herein, and pharmaceutical compositions comprising these compounds. The compounds of formula (I) and pharmaceutical compositions comprising them are useful for treating a disorder for which a V1a antagonist is indicated, in particular, dysmenorrhoea.Type: GrantFiled: May 11, 2010Date of Patent: January 10, 2012Assignee: Pfizer Inc.Inventors: Justin Stephen Bryans, Patrick Stephen Johnson, Lee Richard Roberts, Thomas Ryckmans
-
Publication number: 20100317652Abstract: The present invention provides compounds of formula (I), or pharmaceutically acceptable derivatives thereof wherein the variables Z, Q, Ring A, V, X, Y and Y? are as defined herein, and pharmaceutical compositions comprising these compounds. The compounds of formula (I) and pharmaceutical compositions comprising them are useful for treating a disorder for which a V1a antagonist is indicated, in particular, dysmenorrhoea.Type: ApplicationFiled: May 11, 2010Publication date: December 16, 2010Inventors: Justin Stephen Bryans, Patrick Stephen Johnson, Lee Richard Roberts, Thomas Ryckmans
-
Patent number: 7745630Abstract: Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: Z, O, A, V, Y and Y? are as defined herein; are useful for treating dysmenorreah.Type: GrantFiled: December 10, 2004Date of Patent: June 29, 2010Inventors: Justin Stephen Bryans, Patrick Stephen Johnson, Lee Richard Roberts, Thomas Ryckmans
-
Patent number: 7442795Abstract: A compound of formula (I), or a pharmaceutically acceptable derivative, wherein A, B, V, W, X, Y, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof.Type: GrantFiled: May 1, 2006Date of Patent: October 28, 2008Assignee: Pfizer Inc.Inventors: Justin Stephen Bryans, Patrick Stephen Johnson, Thomas Ryckmans, Alan Stobie
-
Publication number: 20080234252Abstract: Compounds of formula (I), or a pharmaceutically acceptable salt, solvate, ester or amide thereof, wherein R1 represents [CH2]n—R2.Type: ApplicationFiled: May 8, 2006Publication date: September 25, 2008Inventors: Justin Stephen Bryans, Patrick Stephen Johnson, Lee Richard Roberts, Thomas Ryckmans
-
Patent number: 7425569Abstract: Compounds of formula (I), or a pharmaceutically acceptable derivative thereof, wherein R1 and R3 independently represent H, C1-6alkyl, C3-8cycloalkyl, or halogen; R2 represents C1-6alkyl, CF3 or aryl; a represents 1 or 2; R4, R5, R7 and R8 independently represent H, C1-6alkyl, C1-6alkyloxy, CN or halogen, or R4 and R5, or R7 and R8, together with the ring to which they are attached form an aryl or heterocyclic fused ring system; X represents C or N; Y represents CH2 or O; R6 represents H, CN or halo provided that, when X represents N, R6 is absent. The compounds are useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.Type: GrantFiled: October 11, 2007Date of Patent: September 16, 2008Assignee: Pfizer IncInventors: Paul Anthony Bradley, Kevin Neil Dack, Patrick Stephen Johnson, Sarah Elizabeth Skerratt
-
Publication number: 20080188478Abstract: Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: R1 represents a group selected from H, CF3, and C1-6 alkyl (optionally substituted by C1-6 alkyloxy or triazolyl); R2 represents halo; Ring A represents a 5- or 6-membered heterocyclic ring containing at least one N atom (the ring being optionally bridged with two or more carbon atoms); R3 represents a 5- or 6-membered heterocyclic ring containing at least one atom selected from N, O or S, the heterocyclic ring being optionally substituted by one or more groups selected from C1-6 alkyl oxo or NH2, the heterocyclic ring being further optionally fused to a 5- or 6-membered aryl or heterocyclic ring containing at least one atom selected from N, O or S, the fused aryl or heterocyclic ring being substituted by one or more halo atoms; are useful for treating a disorder for which a V1a antagonist is indicated, in particular, dysmenorrhea.Type: ApplicationFiled: April 18, 2006Publication date: August 7, 2008Inventors: Justin Stephen Bryans, Mark Edward Bunnage, Patrick Stephen Johnson, Helen Janet Mason, Lee Richard Roberts, Thomas Ryckmans, Alan Stobie, Toby James Underwood